To characterize EVs derived from patients with leukaemia and healthy donors, Western blot analyses were performed using common EV markers such as CD9 and TSG-101 and the endoplasmic reticulum (ER) membrane marker Calnexin as a negative control. This evidence concerns the gene TSG101 and leukemia.